Seattle Genetics (SGEN) Sets Date with FDA to Review Biologics License Applications for Brentuximab Vedotin
Tweet
Share
E-mailGet Alerts SGEN Hot Sheet
Join SI Premium – FREE
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the U.S. FDA Oncologic Drugs Advisory Committee will review the company’s Biologics License Applications for brentuximab vedotin (ADCETRIS) on July 14, 2011.
The committee plans to review the BLA for the treatment of relapsed or refractory Hodgkin lymphoma during the morning session and the Biologics License Applications for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma during the afternoon session.
The committee plans to review the BLA for the treatment of relapsed or refractory Hodgkin lymphoma during the morning session and the Biologics License Applications for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma during the afternoon session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Agenus drug combo shows 33% three-year survival in colorectal cancer
- Yum! Brands adds Bratspies to board committee
- BioNTech ends colorectal cancer mRNA therapy trial early
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
